Bicster, in addition to being a known welcher, you are also wrong more often than a broken clock.
From the Prospectus Supplement dated February 12th, 2015 under Board and Preemptive Rights; Resale Limitations: "Under the Subscription Agreement with Sarrisa, Sarrisa has agreed not to resell the shares of common stock it purchases for a period of six months from the closing date of the offering."
If memory serves me correctly, Sarissa can NOT sell any APRI ahares for at least 6 months from the close of the financing deal last February.
Why would Abbott mention Vitaros on their website? Abbott no longer owns Vitaros marketing rights in Canada. Mylan does.
Social, I agree that Vitaros will not be pulled off the market and will be a nice revenue generator for years to come. However, I sse Vitaros royalties being much higher that 10 million dollars 24 months from now. France should be a nice market for Vitaros, but how can you estimate 6 million dollars a year in royalies for France and only 3-4 million for the rest of the territories were Vitaros is marketed? I see peak Ex USA Vitaros Royalties being around 40 million dollars at an average royalty of about 13.5 percent, and we can not forget milestone payments.
Royalties should start looking pretty good by Q4 2015 and Q1 2016.
Right now he is Bunt Single Al. . I have a feeling that he's is about to be thrown out attempting to steal second base.
Re: "In Fact, the total royalties for all of 2015 will be less than Pascoe's salary."
There you go again, Al. You attempt to pass your scare tactic statement as fact.
The fact that Sandoz expanded the marketing deal and continues to launch and gain approvals indicates that they are pleased with sales.
Re: "Are they waiting for the room temperature applicator like Canada is? If so, the later part of 2016 will be the soonest"
Al, you should know better than to make comments like this. There is nothing wrong with you taking a profit. Clearly you want back in at a lower price than $2.34, but misleading people about the Vitaros launches in Europe and Canada is just not right..
You should know that Sandoz, a Novartis company, has already launched the Cold Vitaros in Germany, Sweden and Belgium. Sandoz has also ordered product to support Vitaros Launches in Denmark, Finalnd, and Norway. Sandoz thought well enough of Cold Vitaros to achieve maketing approvals on their own in Norway, Finalnd, and Denmark. They also thought well enough of Vitaros to expand the marketing agreement to include some Asia Pacific nations.
You should know that Takeda has launched Cold Vitaros in the United Kingdom,
You should know that Cold Vitaros was shipped to Spain for launch by Recordati.
You should know that Laboratoires Majorelle received Cold Vitaros for their launch in France and they are only awaiting the reimbursement decision which should come very soon.
You should also know that Bracco has ordered Cold Vitaros for Italy.
No, Al, the European Marketing Partners are not waiting for Room Temp Vitaros, It looks like full speed ahead for Cold Vitaros in Europe.
I would not be surprised to see yet another Vitaros launch announcement in Europe this coming week.
In my opinion, the Vitaros launch in Canada was delayed only because of the sale of Abbott's Developed Markets Generics business to Mylan. That deal is expected to close soon. I believe that there is a good chance that Mylan does launch Cold Vitaros in Canada.
I am very pleased with Apricus' acquisition of U.S. Fispemifene rights, and I pretty sure that Alex Denner and Sarissa are too.
Warner Chilcott owned U.S. Vitaros rights and was moving forward with a small clinical studiy wihich the FDA requested. Avtavis bought Warner Chilcott and the study was cancelled.
According to Apricus Biosciences CEO Pascoe, the company is currently in talks with Actavis to move Vitaros forward in the USA. Apricus has developed a Room Temperature Dispenser for Vitaros.. Pascoe said that further clinical development of Vitaros in the USA would be Room Temperature version. Actavis does not hold rights to the Vitaros Room Temp Dispenser.
Actavis is talking to Actavis about reacquiring U.S. Vitaros rights. Another possibility is the two companies come to a licensing agreement regarding the Vitaros RTD.
The cold chain version of Vitaros has launched and continues to launch in Europe. I have heard of no problems with stability in Europe. Do you expect everyone to believe that the product is stable in Europe but not Canada?
Folks like you are here just to muddy the waters.
You should know that Abbott sold their Developed Markets Generics Business to Mylan. The deal is expected to close in the first quarter of 2015. Vitaros was part of the deal. I believe that Mylan will launch Vitaros in Canada.
It seems that Sandoz, a Novartis company, is doing very well with Vitaros in Europe. They have already launched in Germany, Sweden and Belgium. and are preparing to launch in Denmark, Norway and Finland.
Recordati has received product and should be launching in Spain anytime now. Laboratoires Majorelle will be launching Vitaros in France soon. Bracco has ordered product for their launch in Italy.
Sandoz and Apricus recently agreed to expand their marketing agreement to include some Asian Pacific nations. I doubt that Sandoz would do this if they were not having success with Vitaros.
Bic, your last "Feeling" was that APRI PPS would not exceed $2.05. When you get these "feelings" perhaps you should just do the opposite, WELCHER.